Drugs with a negative impact on cognitive functions (part 3): antibacterial agents in patients with chronic kidney disease
Sophie Liabeuf,Gaye Hafez,Vesna Pešić,Goce Spasovski,Mickaël Bobot,Romaldas Mačiulaitis,Inga Arune Bumblyte,Ana Carina Ferreira,Ana Farinha,Jolanta Malyszko,Marion Pépin,Ziad A Massy,Robert Unwin,Giovambattista Capasso,Laila-Yasmin Mani,CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target),Alexandre Andrade,Mustafa Arici,Maie Bachmann,Matthew Bailey,Michelangela Barbieri,Annette Bruchfeld,Inga Bumblyte,Antonello Calcutta,Giovanna Capolongo,Sol Carriazo,Michele Ceccarelli,Adrian Constantin Covic,Ananya De,Pilar Delgado,Nicole Endlich,Matthias Endres,Fabrizio Esposito,Michele Farisco,Quentin Faucher,Andreja Figurek,Denis Fouque,Casper Franssen,Ivo Fridolin,Sebastian Frische,Liliana Garneata,Loreto Gesualdo,Konstantinos Giannakou,Olivier Godefroy,Aleksandra Golenia,Dimitrios Goumenos,Agnė Gryguc,Eugenio Gutiérrez Jiménez,Ewout Hoorn,Pedro Henrique Imenez Silva,Raafiah Izhar,Dearbhla Kelly,Shelli Kesler,Aleksandra Klimkowicz-Mrowiec,Samuel Knauss,Justina Kurganaite,Hélène Levassort,Gianvito Martino,Ziad Massy,Christopher Mayer,Armida Mucci,Alma Mutevelic-Turkovic,Rikke Nielsen,Dorothea Nitsch,Alberto Ortiz,Vasileios Panagiotopoulos,Giuseppe Paolisso,Bojana Pejušković,Marion Pepin,Alessandra Perna,Andrea Perrottelli,Pasquale Pezzella,Merita Rroji Molla,Ivan Rychlík,Giorgos Sakkas,Mariadelina Simeoni,Maria José Soler Romeo,Ana Starčević,Gioacchino Tedeschi,Francesco Trevisani,Evgueniy Vazelov,Carsten Alexander Wagner,Franca Wagner,Christoph Wanner,Andrzej Wiecek,Hong Xu,Miriam Zacchia,Lefteris Zacharia,Irene Zecchino,Carmine Zoccali,Francesco Mattace Raso,Karl Hans Endlich,Norberto Perico,Giuseppe Remuzzi,Francesco Trepiccione,Mark Okusa,Vincenzo Di Marzo,Peter Blankestijn,Kai-Uwe Eckardt,Maximilian Konig
DOI: https://doi.org/10.1093/ckj/sfae174
2024-06-14
Abstract:The relationship between chronic kidney disease (CKD) and cognitive function has received increased attention in recent years. Antibacterial agents (ABs) represent a critical component of therapy regimens in patients with CKD due to increased susceptibility to infections. Following our reviewing work on the neurocognitive impact of long-term medications in patients with CKD, we propose to focus on AB-induced direct and indirect consequences on cognitive function. Patients with CKD are predisposed to adverse drug reactions (ADRs) due to altered drug pharmacokinetics, glomerular filtration decline, and the potential disruption of the blood-brain barrier. ABs have been identified as a major cause of ADRs in vulnerable patient populations. This review examines the direct neurotoxic effects of AB classes (e.g. beta-lactams, fluoroquinolones, aminoglycosides, and metronidazole) on the central nervous system (CNS) in patients with CKD. We will mainly focus on the acute effects on the CNS associated with AB since they are the most extensively studied effects in CKD patients. Moreover, the review describes the modulation of the gut microbiota by ABs, potentially influencing CNS symptoms. The intricate brain-gut-kidney axis emerges as a pivotal focus, revealing the interplay between microbiota alterations induced by ABs and CNS manifestations in patients with CKD. The prevalence of antibiotic-associated encephalopathy in patients with CKD undergoing intravenous AB therapy supports the use of therapeutic drug monitoring for ABs to reduce the number and seriousness of ADRs in this patient population. In conclusion, elucidating AB-induced cognitive effects in patients with CKD demands a comprehensive understanding and tailored therapeutic strategies that account for altered pharmacokinetics and the brain-gut-kidney axis.